Gelonghui July 30?Lepu Medical (300003.SZ)Announced that Shenzhen Kaiwo Electronics Co., Ltd., a wholly-owned subsidiary of the company's AI Division, has independently developedartificial intelligenceThe "electrocardiograph" (OmniECGB120AI) of the deep learning analysis algorithm was approved by the State Drug Administration (hereinafter referred to as "NMPA"). This product is the first product at home and abroad to use AI.ChipThe ECG equipment for automatic analysis of ECG artificial intelligence fills the gap in the products of artificial intelligence electrocardiograph in our country. It is another artificial intelligence NMPA medical registration certificate obtained by the company after the artificial intelligence medical product (AI-ECGPlatform) approved by NMPA for the first time in January this year.
Electrocardiogram is the most simple, fast and economical clinical examination method for cardiovascular disease, and it is the cornerstone of cardiovascular disease examination. Lepu artificial intelligence "electrocardiograph" (OmniECGB120AI) is an intelligent electrocardiograph which integrates the algorithm of ECG artificial intelligence analysis software (AI-ECGPlatform) which has been registered and approved by NMPA on the basis of embedded AI chip. Its biggest advantage is that it can realize ECG collection, fast and accurate AI automatic analysis, and print the whole work flow of ECG examination on an ECG device. By collecting ECG signals synchronously, we can automatically analyze cardiovascular diseases such as arrhythmia, myocardial infarction, ventricular hypertrophy and abnormal ST-T in adults. The AI algorithm of the device is based on artificial intelligence deep learning technology, using tens of millions of levels of ECG big data for training, and the overall accuracy is more than 95%. Lepu's AI-ECG technology has declared a number of invention patents at home and abroad, of which 3 patents have been granted.
After Lepu artificial intelligence "electrocardiograph" (OmniECGB120AI) is approved, it will quickly be commercialized and applied in domestic hospitals, individual clinics, physical examination centers, social health centers, pension institutions and other medical institutions, which not only solves the problem of lack of professional ECG doctors in China, but also liberates the labor force of professional ECG doctors in large hospitals, effectively improve work efficiency and improve diagnosis level. Form an integrated service chain of artificial intelligence ECG analysis and diagnosis technology, realize the localization and rapid ECG analysis and diagnosis of patients in these medical institutions, meet the rigid needs of related medical services, and effectively benefit the vast number of cardiovascular disease patients in China.
